Document is current
Any future updates will be listed below
-
Authors
Ward, Mary
Hughes, Catherine F.
Strain, J. J.
Reilly, Rosie
Cunningham, Conal
Molloy, Anne M.
Horigan, Geraldine
Casey, Miriam
McCarroll, Kevin
O’Kane, Maurice
Gibney, Michael J.
Flynn, Albert
Walton, Janette
McNulty, Breige A.
McCann, Adrian
Kirwan, Laura
Scott, John M.
McNulty, Helene http://orcid.org/0000-0002-4366-6457
-
Funding
Funding for this research was provided by:
Irish Department of Agriculture, Food and the Marine and Health Research Board
Department for Employment and Learning, Northern Ireland
- License Information
-
More Information
Article History
Received: 1 June 2020
Accepted: 10 September 2020
First Online: 11 November 2020
Ethics approval and consent to participate
: TUDA: Ethical approval was obtained from the Office for Research Ethics Committees Northern Ireland (reference number 08/NIR03/113), the Research Ethics Committee in St James’s Hospital, and the Adelaide and Meath Hospital, Dublin. All participants provided written informed consent at the time of recruitment.NANS: The study was approved by the Clinical Research Ethics Committee of the Cork Teaching Hospitals, University College Cork, and the Human Ethics Research Committee of University College Dublin. All eligible and willing participants gave their written consent according to the Helsinki declaration.
: Not applicable.
: There is a patent granted in Europe and pending elsewhere by Ward, McNulty, Strain, Horigan and Scott, on the use of riboflavin in the treatment of hypertension; the other authors have no conflicts of interest to declare.
